Qualigen Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. is a U.S.-listed biotechnology company traded on NASDAQ in the United States, with a corporate base historically associated with Carlsbad, California. For French-speaking investors, it is best understood as a small-cap, high-risk healthcare story whose value proposition has shifted over time from diagnostics toward oncology-focused drug development. The company’s current structure dates to a reverse recapitalization completed on May 22, 2020, when Ritter Pharmaceuticals was renamed Qualigen Therapeutics. The operating and technological heritage, however, comes from Qualigen, Inc., which was originally founded in 1996 in Minnesota before later being reincorporated in Delaware. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1460702/000164117225017212/form10-k.htm?utm_source=openai)) Qualigen’s business model has historically had two pillars: rapid diagnostics and therapeutics. Its best-known legacy asset is the FastPack® platform, a point-of-care quantitative immunoassay system designed for decentralized clinical settings. On the therapeutic side, the company has focused on oncology programs, including QN-247 and RAS-F, and later identified QN-302 as a lead program, described in SEC filings as a G-quadruplex-selective transcription inhibitor. Importantly, the company disclosed that its former FastPack diagnostics business was sold in July 2023 to Chembio Diagnostics, which materially changed the profile of the business and left Qualigen more concentrated on research and development rather than commercial diagnostics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1460702/000149315222008431/form10-k.htm?utm_source=openai)) From a competitive standpoint, Qualigen operates in the crowded oncology biotech space, where success depends on clinical validation, regulatory progress, and access to capital. It does not compete as a diversified commercial pharmaceutical group; instead, it is a development-stage company whose equity case is driven by the optionality of its pipeline and by potential milestone events from preclinical or clinical data. That makes the stock highly sensitive to funding needs, dilution risk, and execution risk, which is typical for emerging biotech names. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001460702/000149315226013434/form10-k.htm?utm_source=openai)) Recent corporate milestones underline this transition. The sale of the FastPack business in 2023, the reverse stock split in 2022, and recent SEC reporting for the year ended December 31, 2025 indicating no trials were performed during that year all point to a company in repositioning mode. For investors tracking SEC Form 4 insider transactions, this matters because insider buys or sells can be informative, but they should be interpreted against the backdrop of a very small, volatile issuer with a strategy still centered on pipeline development rather than operating scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1460702/000149315224013400/form10-k.htm?utm_source=openai))